(Bloomberg) -- Just when it looked like the worst was over for the Spanish family behind one of the world’s biggest medical fortunes, its financial woes plumbed to a new low. The Grifols family ...

to back the take-private of Spanish pharmaceutical producer Grifols SA. Lenders are preparing to send final proposals next week, with the expectation that a bank group will be appointed by the end ...

Canadian fund Brookfield Corp. BN-T plans to offer about €7-billion ($10.4-billion) for Spanish drugmaker Grifols SA after finishing due diligence, news website El Confidencial reported on ...

Global healthcare company Grifols has partnered with BARDA, the Biomedical Advanced Research and Development Authority, to develop the first immune therapy eye drops to prevent the long-term ...

Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasis Grifols surgical bleeding management ...

Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division. Shares traded 4.7% ...

European shares struggle ahead of speeches from ECB policymakers 9:30 AM UTC Canadian fund Brookfield plans to offer about 7 billion euros ($7.4 billion) for Spanish drugmaker Grifols after ...

Grifols (GRFS) has established a partnership with the Biomedical Advanced Research and Development Authority to test investigational ocular surface immunoglobulin eye drops for their ability to ...